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Background. Relapses originating from hypnozoites are characteristic of Plasmodium vivax infections. Thus,
reappearance of parasitemia after treatment can result from relapse, recrudescence, or reinfection. It has been
assumed that parasites causing relapse would be a subset of the parasites that caused the primary infection.
Methods. Paired samples were collected before initiation of antimalarial treatment and at recurrence of par-
asitemia from 149 patients with vivax malaria in Thailand ( ), where reinfection could be excluded, and n p 36
during ﬁeld studies in Myanmar ( ) and India ( ). n p 75 n p 38
Results. Combined genetic data from 2 genotyping approaches showed that novel P. vivax populations were
present in the majority of patients with recurrent infection (107 [72%] of 149 patients overall [78% of patients
in Thailand, 75% of patients in Myanmar {Burma}, and 63% of patients in India]). In 61% of the Thai and
Burmese patients and in 55% of the Indian patients, the recurrent infections contained none of the parasite
genotypes that caused the acute infection.
Conclusions. The P. vivax populations emerging from hypnozoites commonly differ from the populations that
caused the acute episode. Activation of heterologous hypnozoite populations is the most common cause of ﬁrst
relapse in patients with vivax malaria.
Plasmodium vivax is the second most prevalent malaria
parasite in the world, infecting 175 million people each
year, predominantly in Asia and in Central and South
America [1, 2]. P. vivax and Plasmodium ovale differ
from Plasmodium falciparum in that they have a hyp-
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nozoite stage, which persists in the liver and causes
relapses after clearance of the acute blood-stage infec-
tion. P. vivax from tropical regions is characterized by
multiple relapses with short latent periods (3–5 weeks),
whereas parasites from temperate regions usually have
long incubation and latent periods (5–10 months) and
are less commonly associated with relapses. Thebiology
of relapses is poorly understood.
Resistance to chloroquine among P. vivax hasemerged
in Oceania, Southeast Asia, and, more recently, in Cen-
tral and South America [3–8]. Pyrimethamine-sulfa-
doxine resistance is more widespread [9–11]. Assess-
ment of P. vivax treatment responses is essential to
monitor the emergence of resistance. For P. falciparum
malaria, parasite genotyping to distinguishhomologous
parasites (suggesting treatment failure) from heterol-
ogous parasites (suggesting a newly acquired infection)
in recurrent infections is needed to interpret the ﬁnd-
ings of drug efﬁcacy trials conducted within areas of
endemicity [12–15]. Interpretation of recurrences of P.928 • JID 2007:195 (1 April) • Imwong et al.
vivax malaria in drug efﬁcacy trials is complicated by relapses,
which result from reactivation of hypnozoites. If the parasites
causing the relapse arise from a dormant subset of the inoc-
ulated sporozoites that caused the primary infection, then ge-
notyping cannot distinguish relapse from recrudescence. Com-
parison of P. vivax parasites associated with relapses and those
associated with the respective primary infections has been re-
ported previously in a small number of patients: 6 patients in
Canada who had acquired the infection in different areas of
endemicity [16], 10 patients in Brazil [17], and 5 patients in
Thailand [18]. Parasite diversity was assessed using molecular
markers in the ﬁrst 2 studies [19, 20] (pvcs and pvmsp1, and
pvmsp1 alone, respectively), whereas a panel of monoclonal
antibodies was used in the third study. Although it was con-
cluded that parasites associated with primary infection and
those associated with relapse are usually of a similar genetic
composition, evidence for novel genotypesinP.vivaxassociated
with relapses was obtained for 24% of the patients (1 of 6
patients in Canada [16], 2 of 10 patients in Brazil [17], and 2
of 5 patients in Thailand [18]).
The objective of the present study was to characterize large
numbers ( ) of paired primary and recurrent P. vivax n p 149
samples collected in drug efﬁcacy trials, to determine the as-
sociation between primary and relapse infections. The samples
were collected in 3 distinct areas of endemicity: 36 samples in
Thailand, 75 in Myanmar, and 38 in India. In all studies, ef-
ﬁcacious asexual-stage treatment was given, although there are
no recent studies from the study areas in India and Myanmar
to conﬁrm full susceptibility to chloroquine. In Thailand and
Myanmar, no radical treatment (i.e., primaquine) was given.
In Thailand, reinfection could be excluded because there was
no reexposure after treatment, whereas, in Myanmar, reinfec-
tion could not be excluded, although the intensity of trans-
mission was low and recurrences were likely to be relapses. In
India, recurrent episodes were often observed many months
after treatment and could have been either relapses or newly
acquired infections. Two types of genetic markers were used
for genotyping: 2 polymorphic P. vivax genes [19, 20] that were
the focus of polymerase chain reaction (PCR) restriction frag-
ment–length polymorphism (RFLP) analysis and microsatellite
loci present in the genome of P. vivax [21, 22].
MATERIALS AND METHODS
Study Sites and Collection of Blood Samples
Fully informed, written consent to undergo blood sampling
was obtained from each subject. Samples were collected in pro-
spective studies to assess drug efﬁcacy, each of which was ap-
proved by the respective scientiﬁc and ethics committees. Sites
where malaria transmission was low or absent were chosen, to
reduce the possibility that reinfection could be a confounding
factor. The intensity of transmissionof P.vivaxinDawei,Myan-
mar, and in periurban Calcutta, India, has not been assessed
formally recently; however, on the basis of a combination of
incidence, prevalence, and clinical-spectrum data, the intensity
of transmission is thought to be low (close to 1 infectious bite
per person per year). There is no malaria transmission in or
near Bangkok.
Thailand. Blood samples were collected from adult male
patients who, between 1992 and1998, presentedtotheBangkok
Hospital for Tropical Diseases with acute symptomatic P. vivax
malaria. Most patients came from the western border of Thai-
land, where recent large studies have conﬁrmed full suscepti-
bility to chloroquine in P. vivax and a relapse rate of 50%, with
a mean interval of 3 weeks to the ﬁrst relapse if rapidly elim-
inated antimalarials are given [9, 23]. Chloroquine suppresses
the ﬁrst relapse but not the second relapse; therefore, after
chloroquine treatment, recurrences of parasitemia in Thailand
occur ∼6 weeks after treatment [9, 23]. Patients were randomly
allocated to receive different antimalarial treatment regimens
(table 1). The patients were kept under daily parasitological
and clinical observation for 28 days. Blood samples were col-
lected at admission, before and after the start of treatment, and
at recurrence of P. vivax parasitemia. The samples were frozen
and stored at 30 Co r70 C until DNA extraction. Two
characteristics of this study are especially useful for later in-
terpretation of the results from studies conducted in areas of
endemicity. First, because the study was conducted in a hospital
setting in Bangkok, where there is no P. vivax transmission,
reinfection can therefore be excluded. Second, detailed infor-
mation on the efﬁcacies of antimalarial treatment with and
without primaquine treatment (which ensures radical cure)
suggested that recrudescence was very unlikely [9, 24]. There-
fore, these sample pairs allowed us to examine the genotypes
of parasites causing relapse infections.
Myanmar. Over a 5-month period (December2002through
April 2003), 75 patients who were infected with P. vivax were
recruited from Dawei in Myanmar. Malaria is perennial, with
low-intensity transmission (entomological inoculation rate, ∼1
infectious bite per person per year). Most cases of malaria were
seen during the rainy season, which peaks from June to August.
The majority of cases (180%) occurred in children 15 years of
age and in adults. All patients received standard chloroquine
treatment (10/10/5 mg base/kg divided over 3 days) (table 1).
Only the ﬁrst dose was observed. Blood samples obtained by
ﬁngerprick were collected from patients before treatment and
at recurrence of vivax parasitemias after treatment. Patients
were monitored until day 28 after treatment. Hence, recru-
descence, relapse, or newly acquired infections wereallpossible.
For 9 patients, recurrent parasitemia was recorded either early
(between day 14 and 19 after treatment) or late (between day
43 and 49 after treatment), whereas, for the remainder of theRelapses of P. vivax Infection • JID 2007:195 (1 April) • 929
Table 1. Antimalarial drugs administered in the 3 studies.
Study site, drug Treatment regimen Patients, no.
Thailand
Quinine sulfate 10 mg of salt/kg 3 times daily for 7 days 3
Halofantrine 8 mg base/kg 3 times in 1 day 1
Artesunate 3.3 mg/kg (adult dose, 200 mg) on the ﬁrst day and then 1.65 mg/kg (adult dose,
100 mg daily) for 4 additional days
30
Artemether 2.7 mg/kg (adult dose, 160 mg) on the ﬁrst day and then 1.3 mg/kg daily (adult
dose, 80 mg daily) for 4 additional days
2
Myanmar, chloroquine Chloroquine (10/10/5 mg base/kg) divided over 3 days and artesunate (2 mg/kg/day)
for 7 days in case of failure
75
India
Chloroquine 10 mg of base/kg, followed 6 h later by 5 mg of base/kg, and then by 2 doses of
5 mg/kg every 24 h
12
Chloroquine and primaquine
For 5 days Same dose of chloroquine as that used for chloroquine-only regimen and primaquine
(adult dose, 15 mg of base daily) for 5 days
12
For 14 days Same dose of chloroquine as that used for chloroquine-only regimen, followed by
primaquine (adult dose, 15 mg of base daily) for 14 days
14
patients, recurrent parasitemia was recorded between days 21
and 30 after treatment.
India. The study involved 155 men with P. vivax malaria
in Calcutta, India. Thirty-eight patients were randomly allo-
cated to 3 oral treatment groups: chloroquine alone or 2 reg-
imens involving chloroquine and primaquine (table1).Patients
were excluded from the study if they had glucose-6-phosphate
dehydrogenase deﬁciency. All patients were monitored weekly
until day 28 after treatment and then monthly thereafter for
18 months. In Calcutta, P. vivax is endemic, although trans-
mission intensity is low. Therefore, in this study, relapse, re-
crudescence, and new infections were also all possible.Thetime
to reappearance was longer (mean, 130 days; median, 77 days;
range, 45441 days) than that noted in Thailand or Myanmar.
In Thailand, Myanmar, and India, resistance to the drugs
used for treatment was unlikely. Therefore, although some re-
crudescences resulting from inadequate drug absorption or un-
usual disposition kinetics may have occurred, most recurrent
infections were probably either relapses or, possibly, newly ac-
quired infections; in Bangkok, such infections must have been
relapses.
DNA Template Preparation
DNA was puriﬁed from blood samples by use of the com-
mercially available DNA Blood Kit (Qiagen). Dry blood spots
were collected from Myanmar and India and were puriﬁed
using the QIAamp DNA kit (Qiagen). The ﬁnal volume of the
DNA solution used as a template for the ampliﬁcationreactions
was 2 mL, which is equivalent to either 2 mL of whole blood
(frozen whole-blood samples collected from Thai patients) or
0.3 mL of whole-blood spot (dry blood spots collected from
patients in Myanmar and India). Conﬁrmation of the micro-
scopic diagnosis of P. vivax infection and testing for the pres-
ence of other Plasmodium species involved the use of a PCR-
based protocol described elsewhere [25].
Genotyping of P. vivax
We ampliﬁed 2 polymorphic antigenic markers: the pvcs gene
and the central fragment (F2) of the pvmsp1 gene. Primers,
ampliﬁcation conditions, and digestion reactions for the 2 loci
have been described elsewhere [19].
P. vivax genome sequence data for the Salvador I strain were
obtained from The Institute for Genomic Research (TIGR)
through the P. vivax Genome Project Web site [26]. Tandem
repeats were identiﬁed using the Tandem Repeats Finder pro-
gram [27, 28]. Microsatellite primers were designed using the
primer3 program [29], and all forward primers were labeled
with ﬂuorescent dye. The sequences and the dyes used for
labeling the different loci are presented in table 2.
A seminested PCR approach was adopted for all the frag-
ments. All ampliﬁcation reactions were performed in a total
volume of 10 mL and in the presence of 10 mmol/L Tris-HCl
(pH 8.3), 50 mmol/L KCl, 250 nmol/L of each oligonucleotide
primer, 2.5 mmol/L MgCl2, 125 mmol/L of each of the 4 deoxy-
nucleoside triphosphates, and 0.4 U of TaKaRa polymerase
(TaKaRa BIO). Primary ampliﬁcation reactions were initiated
with 2 mL of the template genomic DNA prepared from the
blood samples, and 1 mL of the product of these reactions was
used to initiate the secondary ampliﬁcation reactions. Forward
and reverse oligonucleotides were used in the primary reaction,
whereas internal and reverse oligonucleotides were used in the
secondary reaction. The cycling parameters for PCR were as
follows: initial denaturation for 5 min at 95 C preceded an-
nealing performed for 30 s at 52 C, extension performed for930 • JID 2007:195 (1 April) • Imwong et al.
Table 2. Primers used for microsatellite genotyping of Plasmodium vivax parasites.
TIGR ID
Repeat
unit, bp Motif
Cycles, no.
Primer Sequence (5
 r3
 ) Size,
a bp Labeled Nested 1 Nested 2
14.297 3 AAG 25 25 Forward TGACATCTTTCAAATATTCCTTT 200
Reverse TGAAAAATGTTCCGCTACTT
Internal TACACCCTTTAGGTCCTCGT PET
1.501 7 GGTGAGA 25 20 Forward TCCTGTAACTCCTGCTCTGT 120
Reverse CTTACTTCTACGTGCCCACT
Internal AATTGTAGTTCAGCCCATTG 6FAM
3.502 8 AACGGATG 25 25 Forward CCATGGACAACGGGTTAG 168
Reverse TCCTACTCAGGGGGAATACT
Internal GTGGACCGATGGACCTAT PET
NOTE. See the “Genotyping of P . vivax” subsection of Materials and Methods for information on polymerase chain reaction protocols. 6FAM,
6-carboxyﬂuoroscein; ID, identiﬁcation; PET, proprietary ﬂuorochrome dye; TIGR, The Institute for Genomic Research.
a No. of base pairs of these loci in the Salvador 1 genome sequence.
Table 3. Overall classiﬁcation of the genotyped paired samples.
Country
Days to recurrence,
median (range) All Different
a Related
b Novel
c
Myanmar 28.0 (14–49) 75 46 (61) 29 (39) 55 (73)
Thailand 21.0 (13–28)
d 36 22 (61) 14 (39) 28 (78)
India 76.5 (45–441) 38 21 (55) 17 (45) 24 (63)
All … 149 89 (60) 60 (40) 107 (72)
NOTE. Data are no. (%) of paired samples, unless otherwise indicated.
a None of the alleles detected in pretreatment samples was observedin theposttreatmentsamples
for any 1 of the 5 markers used.
b For all 5 markers, at least 1 of the alleles detected in pretreatment samples was also observed
in the posttreatment samples.
c The no. of the samples classiﬁed as “related” but for which 1 of the microsatellite loci provided
evidence that 1 of the alleles detected in the recurrent episode sample were not present in the
admission sample, added to the no. of samples classiﬁed as “different.”
d The day of recurrence was not recorded for 4 of the 36 Thai patients, although a blood sample
was collected.
30 s at 72 C, and denaturation performed for 30 s at 94 C.
After a ﬁnal annealing step was performed, followed by 2 min
of extension, the reaction was stopped. PCR products were
stored at 4 C until analysis.
We measured variation in microsatellite allele size by use of
an ABI 3100 genetic analyzer (PE Applied Biosystems) and
comparison with a size standard (GeneScan 500 LIZ; Applied
Biosystems). We used GeneScan and Genotyper software (Ap-
plied Biosystems) to measure allele length and to quantify peak
heights. Multiple alleles per locus werescorediftheywere133%
of the height of the predominant alleles present.
We initially selected 6 loci that provided very clean ampli-
ﬁcation, with no stutter peaks, on the basis of ampliﬁcation of
6 samples from Thailand. These loci were 9.264, 14.297,13.239,
1.501, 3.502, and 3.503. Loci were named using their chro-
mosomal location, followed by a numerical identiﬁer. Two of
these loci showed lowpolymorphismwithhigh-frequencycom-
mon alleles. These loci were dropped because they were un-
informative. One other locus (TIGR identiﬁcation [ID] 9.264)
was also eliminated, because strong stutter peaks wereobserved
in some samples, generating spurious data. The set of 3 loci
(TIGR IDs 1.501, 3.502, and 14.297) was used for analysis of
all paired samples.
We included multiple,randomlydistributed,negativecontrol
samples (human DNA or no template) in each ampliﬁcation
run. Asubsetof thesamples( )wereanalyzedintriplicate n p 10
to conﬁrm the consistency of the results obtained. All pairs of
primers were tested for speciﬁcity by use of genomic DNAfrom
P. falciparum or humans. Serial dilution of genomic DNA was
performed to test the sensitivity of primers.
Comparison of Acute Infection and Recurrence Genotypes
We compared the genotypes of pre-andpost-treatmentsamples
for 36 paired samples from Thailand, 75 pairs from Myanmar,
and 38 pairs from India. On the basis of analysis of thesepaired
samples, we classiﬁed the parasite populations as being genet-Relapses of P. vivax Infection • JID 2007:195 (1 April) • 931
Table 4. Patterns of variation in the 3 microsatellite chromosome loci used.
Study site
Paired
samples, no.
Alleles
at each locus, no.
Frequency of the most
common alleles, % 1 He Maximum
probability
a 1.501 3.502 14.297 1.501 3.502 14.297 1.501 3.502 14.297
Myanmar 75 10 10 6 30 28 34 0.14 0.17 0.23 0.005
Thailand 36 11 13 9 22 17 25 0.12 0.12 0.17 0.002
India 38 14 7 7 25 30 30 0.08 0.18 0.19 0.002
NOTE. The Institute for Genomic Research identiﬁcation is used to identify each locus. Variation in the 3 markers was assessed by counting
the nos. of different alleles present in each location and by measuring expected heterozygosity (He; the chance of drawing 2 different alleles
from a population sample) by use of the formula , where p is the frequency of the ith allele and n is the sample size.
2 H pn/(n1)(1Sp ) ei
a Maximum probability of 2 parasite clones carrying the same microsatellite alleles by chance, assuming random association between alleles
at each locus.
Table 5. Genetic complexity of Plasmodium vivax populations present in the paired samples.
Study site
Mean MOI for samples
(% of samples or patients with single genotype)
Mean MOI for
samples with
novel genotypes
a At admission At recurrence All
Myanmar 1.87 (35) 1.55 (51) 2.63 (43) 0.77
Thailand 1.69 (47) 1.53 (56) 2.67 (51) 0.97
India 1.11 (89) 1.24 (79) 1.84 (84) 0.74
NOTE. MOI, minimum no. of different parasite genotypes present.
a Observed in samples obtained at recurrence.
ically related or different, by use of the following criteria for
each locus.
Related parasite population. All or a subset of the alleles
detected in pretreatment samples were also observed in the
posttreatment samples. For “related” samples,themicrosatellite
genotyping data were furtherusedtoidentifypatientsforwhom
there was also evidence of a novel genotype(s) in the recurrent
sample not found among genotypes identiﬁed in the corre-
sponding admission sample.
Different parasite populations. For any one locus, none
of the alleles detected in pretreatment samples were observed
in the posttreatment samples. If a paired sample was classiﬁed
as “different” for any one of the markers considered (antigen
genes or microsatellite loci), then the 2 parasite populations
were considered to be genetically different.
RESULTS
Informative PCR-RFLP analysis was conducted for 131 of the
149 paired samples. For 50 (38%) of these 131 samples (42%
of samples from Myanmar, 33% of samples from Thailand,and
34% of samples from India), the parasite populations in the
samples obtained at admission and thoseobtainedatrecurrence
were genetically distinct. The pvmsp1 locus alone was infor-
mative in 35 of this subset of 50 samples, and it was found to
be more informative than pvcs. Analysis of microsatellite loci
revealed a higher proportion of paired samples (50% [i.e., 75
of 149 paired samples]) that were classiﬁed as being genetically
distinct (56% of samples from Thailand, 47% of samples from
Myanmar, and 53% of samplesfromIndia).The3microsatellite
markers contributed equally to this classiﬁcation. When the
results obtained independently by use of each method (micro-
satellite genotyping and PCR-RFLP analysis) were compared,
the classiﬁcations were found to be concordant for 90 (69%)
of the 131 pairs analyzed (54 pairs were classiﬁed as related,
and 36 were classiﬁed as different). Microsatellite analysis al-
lowed an additional 27 paired samples to be distinguished that
differed in parasite genotype composition, andPCR-RFLPanaly-
sis allowed another 14 paired samples to be distinguished (8
samples through pvmsp1 alone).
We combined results from the 2 genotyping approaches (ta-
ble 3). Overall, 89 (60%) of 149 paired samples were genetically
distinct from each other (61% of samples from Thailand, 61%
of samples from Myanmar, and 55% of samples from India).
Microsatellite genotyping revealed that, in some cases, new par-
asite genotypes appeared in the infection causing recurrence
together with the genotype causing the primary infection.
Therefore, at recurrence, novel P. vivax populations appeared
in 107 (72%) of 149 patients (78% of those from Thailand,
73% of those from Myanmar, and 63% of those from India).
The overall diversity of P. vivax was determined, on the basis
of microsatellite genotyping, for the samples obtained from the
3 sites (table 4). Despite low transmission intensity, mixed ge-
notype infections were common (table 5). The arithmeticmean
MOI (minimum number of different parasite genotypes pres-932 • JID 2007:195 (1 April) • Imwong et al.
ent) in primary infections was similar in Thailand and Myan-
mar (mean MOI, 1.69 and 1.87, respectively) and was higher
than that noted for samples collected from India (mean MOI,
1.11). A similar pattern was observed for the samples obtained
at recurrence of infection (mean MOI: 1.53 for samples from
Thailand, 1.55 for samples fromMyanmar,and1.24forsamples
from India). The proportion of samples with single genotypes
noted at admission and at recurrence of infection did not differ
signiﬁcantly at the 3 study sites. On average, 0.97, 0.77, and
0.74 new genotypes were detected in the samples obtained at
recurrence of infection in patients in Thailand, Myanmar, and
India, respectively. When these results are combined, the ma-
jority of patients appear to have carried multiple genotypes
during the observation period. In Thailand, 49% of patients
carried 11 genotype (mean MOI, 2.67); in Myanmar, 57% car-
ried 11 genotype (mean MOI, 2.63); and in India, 16% carried
11 genotype (mean MOI, 1.84). In India, where patients were
followed for 11 year, median times to reappearance tended to
be shorter for sample pairs carrying the same allele at all 3 loci
(median time to reappearance, 64 days) than in pairs with
different alleles at 1 of the loci (median time to reappearance,
80 days); however, this difference wasnotstatisticallysigniﬁcant
( , Mann-Whitney U test). Median times to reappear- P p .14
ance were similar for patients treated with chloroquine alone
(91 days) or with chloroquine and primaquine either for 5 days
(71.5 days) or 14 days (73 days).
DISCUSSION
P. vivax infections that recur after drug treatment may have 1
of 3 origins: recrudescenceoriginatingfromasexualblood-stage
parasites that survived drug treatment, reinfection resulting
from a new mosquito inoculation, or relapse arising from the
dormant liver stages (hypnozoites). In the present study, we
conducted what, to our knowledge, is the ﬁrst extensivewithin-
patient comparative genetic analysis of primary infection and
ﬁrst relapse P. vivax populations. Transmission intensities in
the 3 Asian countries were low, making early reinfection un-
likely, and efﬁcacious treatment regimens were used, making
recrudescence unlikely [23, 30]. In the Thailand study, rein-
fection was impossible, so recurrences were certainly relapses,
whereas, at the other 2 study sites, reinfection could not be
excluded. Contrary to general expectation, the P. vivax infec-
tions causing relapses were usually caused by parasitesthatwere
genetically distinct from those that caused the acute infection.
This unexpected observation provides novel insights into the
biology of relapses and, if conﬁrmed as a general phenomenon,
confounds the use of parasite genotyping analyses to support
in vivo drug efﬁcacy trials.
The majority of episodes of recurrent vivax malaria in the
present study presumably arose from hypnozoites that became
reactivated after treatment of the initial acute infection. There
are 2 generic explanations for this: either (1) there was simul-
taneous inoculation of different genotypes by a singlemosquito
or by different mosquitoes within a short period (i.e., 1 or 2
days); or (2) multiple inoculations occurred over a longer pe-
riod, and the acute infection activated dormant hypnozoites
originating from an earlier inoculation. If the ﬁrst explanation
is correct, then either the primary infection with the relapse
genotype is at a density below the PCR-genotyping detection
level or there is no primary infection and these later emerging
parasites have a longer incubation period. The hypnozoites of
different parasite strains may have different ﬁxed periods of
dormancy, as in the P. vivax strains from temperate andtropical
zones. However, how activation of the hypnozoites of heter-
ologous genotype occurs is unknown. Previously acquired ge-
notype-speciﬁc immunity might preferentially suppress onege-
notype but would be inconsistent with the appearance of the
suppressed genotype some 3 weeks later. A more likely expla-
nation is that genotype-speciﬁc immunity developsonlyagainst
the predominant blood-stage parasites in the mixed-genotype
primary infection and that it preferentially suppresses this ge-
notype when it later emerges at relapse. This would imply a
threshold parasitemia for the induction of protective antibody
responses. More information on the P. vivax genotypes carried
by mosquitoes would help toresolvethequestionofinoculation
times. More-sensitive genotype-speciﬁc detection methods
would resolve the question of whether initial infectionscontain
more genotypes. Irrespective of the timing of inoculation,these
data indicate that the hypnozoitesactivatedaftertreatmentusu-
ally arise from a subset of sporozoites different from that which
caused the initial infection. This implies an unexpected and re-
markable regulation of within-host phenotypic behavior among
different strains.
In conclusion, genotyping analysis of vivax malaria indicates
a high rate of mixed-genotype infections even in settings where
transmission is low, and it suggests a hitherto unsuspectedphe-
nomenon of heterologous activation of hypnozoite popula-
tions. These observations, as well as those presented in a com-
panion report [31], provide important insights into the biology
of the dormant stages of P. vivax.
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